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Summary
Purpose: Intracortical microinjection of fluorocitrate, a reversible inhibitor of glial tricarboxylic acid (TCA), results in impaired glial metabolism and epileptic seizures. To determine the potential contribution of epileptic activities to the metabolic properties of fluorocitrate, we investigated the seizure-inducing property of fluorocitrate at different doses. Methods: Twenty-seven male Sprague Dawley rats (250-400 g) were studied with chronically implanted electrodes and cannulae in the occipital cortices. A week after surgery, awake behaving rats were injected with 0.2 ml solution containing various concentrations of fluorocitrate or saline in the right occipital cortex; two shamtreated animals did not receive an injection. EEG was recorded with implanted electrodes. Thionin staining was used to verify injection sites. Twenty rats underwent immunohistochemistry for glial fibrilary acidic protein (GFAP) and neuronal nuclearspecific antigen (NeuN) 48 h after the injections. Results: Seizures developed within an hour of injection in all the rats that received !0.8 nmol fluorocitrate and 2 of 4 rats that received 0.4 nmol fluorocitrate. Five of 12 animals that received !1.2 nmol fluorocitrate experienced status epilepticus. There was a significant increase in GFAP staining at the injection site in doses !0.8 nmol fluorocitrate. There was only mild neuronal loss revealed by NeuN staining at the injection site in the animals that had received 1.6 nmol flourocitrate. Conclusion: This study shows that fluorocitrate results in focal epileptic seizures with secondary generalization in a dose-dependent manner, including low doses of this agent previously used for studies of brain metabolism. # 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Introduction
Epileptic seizures are evolving repetitive rhythmic discharges associated with behavioral changes [1] [2] [3] [4] while interictal epileptic spikes (IEDs) are abnormal hypersynchronous electrical discharges of a population of neurons in a small region of the brain with no or minimal propagation so that they usually do not alter behavior. 5 Electroencephalogram (EEG) remains the primary tool in the study of epileptic activities. EEG tracing records the extracellular electrical field potentials generated by a population of cortical neurons, which amplifies small changes in the voltage difference between two inputs electrodes and displays them continuously with great temporal resolution. 6 More than 30 percent of patients with epilepsy have inadequate control of seizures with drug therapy and are considered to have intractable epilepsy with recurrent seizures. 7 This underlies our limited understanding of the factors that trigger seizures in epileptic patients and requires greater attention to the potential role of the non-neuronal elements of the nervous system. Astroglial cells play a key role in energy metabolism and cycling between the inhibitory and excitatory neurotransmitters through glutamate-glutamine-gamma aminobutyric acid (GABA) shunt. 8 The participation of glial cells in seizure generation is not well known. Fluorocitrate is a reversible blocker of aconitase in tricarboxylic acid (TCA) cycle, which preferentially inhibits the glial TCA cycle and impairs glial metabolism. Fluorocitrate inhibits glial metabolism in in vitro preparations at doses ranging from 5-100 mM. 9 Intracerebral injection of fluorocitrate reduces glial glutamine, 10, 11 but its effect has been demonstrated at a relatively larger volume of about 1 ml of 1 mM solution (i.e. 1 nmol). 12 Even larger intrathecal volume (i.e. 5 ml of 1 mM or 5 nmol) and similar systemic doses of fluorocitrate has been shown to induce seizures. 13 Direct spread of flourocitrate in such large volumes may result in loss of its cellular selectivity. In a previous study, 11 seizures resulted from a high concentration (6.4 mM in 0.125 ml or 0.84 nmol) of fluorocitrate injected intracortically into the frontal cortex in acute experiments. However, there are no published data on the epileptic properties of different doses of fluorocitrate despite its popularity to study cerebral metabolism using modern tools such as magnetic resonance spectroscopy (MRS). 9 The purpose of this study was to determine epileptic property of a fixed volume of fluorocitrate at various doses. Fluorocitrate was injected into the occipital cortex of SD rats in the present study.
Materials and methods

Animal preparations
This study was approved by the University of Western Ontario's Institutional Animal Care and Use Committee. Twenty-seven adult male Sprague Dawley (SD) rats (Charles River, QE) with body weight ranging from 250-400 g were housed in a 12 h dark and 12 h light cycle and had food and water ad libitum. The animals were anesthetized with sodium pentobarbital (65 mg/kg, intraparotenially (IP), MTC Pharmaceuticals, Cambridge, ON) and atropine methylnitrate (0.12-0.17 mg/kg, IP) was injected to prevent fluid accumulation in the 484 S.M. Mirsattari et al. 16 , purity 95%, Sigma-Aldrich Canada Ltd., Oakville, ON). There were !3 animals in each group, plus 2 sham-treated rats that underwent the same surgery but they did not receive any injections (Table 1) . On the day of experiment, 0.2 ml of saline or 0.2, 0.4, 0.8, 1.2, and 1.6 nmol of fluorocitrate was injected through the right occipital canuula 1.6 mm below the skull surface using a polyethylene 50 tube attached to a Hamilton microlitre syringe (72-1742, 0.5 ml volume with a 32 gauge needle, Harvard Apparatus, Inc., Saint Laurent, QE). The canuulae in the left occipital lobe were used in two cases that the right-sided canuulae were blocked. EEG was recorded by a Grass Instruments Model 8-10 polygraph or a digital EEG (XLTEK, Oakville, ON) using a laptop computer. EEG was monitored for maximum of 6 h (i.e. till the termination of epileptic discharges) after each injection and again half an hour per day until their sacrifice 48 h after the injections. They were then given a bolus of 45% urethane 1.3 g/kg IP (Sigma-Aldrich Inc., St. Louis, MO) and perfused transcardially with 100 ml of 0.9% saline followed by 500 ml of fixative consisting of 4% freshly depolymerized paraformaldehyde (BDH Inc., Toronto, ON) in 0.1 M phosphate buffer (PB, pH 7.4) using a perfusion pump (Masterflex C/liter TM pump A gliotoxin model of seizures 485 system, Cole-Parmer Instrument Co., Vernon Hills, IL) via the left ventricle of the heart for histologic confirmation of the injection site using thionin staining and subsequent immunocytochemical examination.
Immunohistochemistry
Brain of each animal was removed and cryoprotected in 18% buffered-sucrose for subsequent histological studies. Coronal sections (40 mm) through the entire brain were cut on a freezing microtome, collected in PB, and kept in storage solution containing 30% glycerol, 30% ethylene glycol (SigmaAldrich Inc., St. Louis, MO) in 0.1 M PB at À20 8C. for 1 h at room temperature. After washing in PB, they were incubated in the chromogen 3,3 0 -diaminobenzidine tetrahydrochloride (DAB; SigmaAldrich Inc., St. Louis, MO) and then hydrogen peroxide (0.003%) was added to initiate the peroxidase reaction. Sections were washed, mounted on chrome-alum-coated slides, and allowed to air dry. They were then dehydrated in a series of ascending alcohols (70%, 95%, 100% twice for 2 min each), cleared in xylene for 5 min twice and coverslipped with Entalan mounting medium (BDH Inc.). To control for specificity of immunostaining, some sections were processed as above but without the primary or secondary antibody. The immunohistochemistry method for NeuN followed previously published. 16 Immunohistochemical labeling was examined using an Axioskop miscroscope (Zeise) under transmitted light, images were photographed and number of NeuN-labeled neurons were quantified in 200 mm width axial strip of the occipital cortex using Image J Image Analysis Software (NIH), while GFAP-labeled cells in this area were quantified by direct visual counting. Quantitative data were analyzed using one-way ANOVA followed by Turkey's post hoc test with alpha set at 0.05.
Results
All 15 rats injected with !0.8 nmol of fluorocitrate and 2 of the 4 rats with 0.4 nmol flourocitrate developed seizures within an hour of the injection, but none of the 3 rats injected 0.2 nmol of fluorocitrate experienced seizures (Table 1 and Fig. 1) . Two of 5 rats that received 1.2 nmol of fluorocitrate and 3 of 7 rats that received 1.6 nmol of fluorocitrate developed status epilepticus (SE) with violent motor seizures lasting greater than 1 h and required diazepam 5 mg/kg IP to terminate the seizures. These rats developed seizures within 1 min of injecting fluorocitrate. The average delay to the onset of the seizures was 30 min. None of the rats had seizures during the subsequent recording days, except for the recurrence of a single motor seizure in one rat 24 h after receiving 0.8 nmol of fluorocitrate. There was a dose-dependent increase in the intensity of the seizures and they frequently become secondarily generalized. During the seizures, the animals either had motionless stare or violent jumps and running in circles in the cage. There were very few IEDs and they were seen with fluorocitrate doses of !0.8 nmol and only within the first 6 h of the recording. Sham-treated animals and those receiving saline injections did not have any epileptic discharges at any time of the recording.
The injection sites were verified by thionin staining in all the animals. There was a dose-dependent significant increase in GFAP staining at the injection site with enlarged astrocytes that had swollen processes in all the study animals that received !0.8 nmol of fluorocitrate (Figs. 2 and 3) . Only minimal GFAP staining at the injection site was seen with 0.4 nmol of fluorocitrate but none with 0.2 nmol of fluorocitrate, saline injection, or sham-treated animals (Table 2) . NeuN staining demonstrated minimal neuronal loss at the injection site only with the highest dose of fluorocitrate (i.e. 1.6 nmol) (Fig. 4) . Otherwise, there was no neuronal loss ( Table 2) .
Discussion
Fluorocitrate induced a dose-dependent epileptic activity in SD rats. At low doses (0.4-0.8 nmol), A gliotoxin model of seizures 487 focal seizures with secondary generalization resulted. At high doses (1.2-1.6 nmol), SE was found in about half the injected animals. Epileptic spikes were exceedingly infrequent and seizures were either associated with motionless stares or violent motor signs (jumping and running in circles). This study confirms that glial cells are important in generating epileptic discharges. Therefore, the diverse nature of human epilepsy 17 and animal models may be due to varying contributions of the glia cells and neurons.
Willoughby et al., 11 originally reported that epileptic discharges in the frontal cortex were induced with local injection of 0.84 nmol of fluorocitrate, resulting in motor convulsions in 4 of 7 injected rats. However, Willoughby et al., 11 injected fluorocitrate under 2% halothane anesthesia, and while the EEG and behavior were observed after the cessation of halothane, the surgical procedure and lingering halothane could have affected the EEG and behavioral responses. By using chronically implanting electrodes, the present study established that a lower dose of fluorocitrate induced epileptic discharges and a higher dose induced SE.
The exact mechanisms of glial-mediated seizures remain to be determined. 18 However, extracellular glutamate and potassium (K + ), which are normally cleared by glial cells, are likely important contributors. [19] [20] [21] Fluorocitrate disrupts glial function and allows local accumulation of glutamate and K + , partly derived from normal activity, such that epileptiform activity may arise. Synaptic transmission, gap junctions, ephaptic transmission, antidoromic spread, and ionic field potentials [22] [23] [24] [25] [26] may all play a role in seizure spread induced by fluorocitrate, similar to seizures induced by other agents. Future studies that employ combination of fluorocitrate and other agents will be valuable in understanding the interaction of neural and glial elements in generating, maintaining, and propagating epileptic discharges.
The high incidence of secondarily generalized seizures and SE in fluorocitrate-induced seizures demonstrates a potentially important role for the glial cells in the rapidly propagating seizures, SE, and medically refractory seizures. There was a relative paucity of epileptic spikes in the animals injected with fluorocitrate, which can occur in some epileptic patients. 17 Low doses of fluorocitrate that do not cause seizure can be used to study early metabolic changes that may lower seizure threshold. The epileptic properties of flourocitrate
